Thomas Goslin

Sanguine

Sanguine Biosciences bridges the gap between researchers and patients. By empowering our growing donor community of 70,000+ research-ready, recallable participants and 100+ diverse patient advocacy groups to participate in biomedical research, we enable translational scientists and clinicians to develop life-changing therapies through direct-to-patient engagement, in-home collection of fully annotated biospecimens, and longitudinal study design. Recent additions of disease-state leukapheresis products, specimen processing, and analytical laboratory services further cement Sanguine as the premier partner for translational and cell & gene therapy research. Referenced in over 140 publications, Sanguine studies have appeared in high-impact journals, including Science, Nature, NEJM, Nature Medicine, and Science Translational Medicine. For the past three years, Sanguine has received the prestigious designation of a "Great Places to Work" company. In 2022, Sanguine was designated #2038 on the Inc. 5000 America's Fastest Growing Private Companies list and achieved recognition on Fortune's Best Small Places to Work. Popular media outlets featuring Sanguine include the Fox News Channel, The Washington Post, Inc.,The Boston Globe, Inc., and many others.